Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 569 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: K8 Clear all
Terminated Phase 4 Interventional Results available

Early Antibiotics After Aspiration in ICU Patients

NCT05079620
View directory record Official record
Conditions
Aspiration, Aspiration Pneumonia
Interventions
Ceftriaxone, Amoxicillin clavulanic acid, Cefepime, Vancomycin, Levofloxacin
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 30, 2026, 7:16 AM EDT
Terminated Phase 3 Interventional Results available

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections

NCT01110408
View directory record Official record
Conditions
Complicated Urinary Tract Infections or Pyelonephritis
Interventions
Doripenem, Doripenem placebo, Cefepime, Cefepime placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Little Rock, Arkansas • Oakland, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 30, 2026, 7:16 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Use of Perioperative Antibiotics in Endoscopic Sinus Surgery

NCT03369717
View directory record Official record
Conditions
Chronic Sinus Infection
Interventions
Amoxi Clavulanate
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 30, 2026, 7:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fasted Conditions

NCT01216852
View directory record Official record
Conditions
Hypertension
Interventions
Losartan Potassium
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 30, 2026, 7:16 AM EDT
Completed No phase listed Observational

Replication of the TRANSCEND Antihypertensive Trial in Healthcare Claims Data

NCT04354376
View directory record Official record
Conditions
Hypertension
Interventions
Loop diuretics, thiazides, dihydropyridines, Telmisartan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years and older
Enrollment
40,048 participants
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 30, 2026, 7:16 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

NCT06733675
View directory record Official record
Conditions
Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI), FDC
Interventions
Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil, Esomeprazole, amoxicillin-clavulanate
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 30, 2026, 7:16 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

NCT05620784
View directory record Official record
Conditions
BPH With Urinary Obstruction, BPH, Hematuria, Same Day Discharge
Interventions
Furosemide
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 30, 2026, 7:16 AM EDT
Terminated Phase 2 Interventional Results available

Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer

NCT00429858
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
S-1, gemcitabine hydrochloride
Drug
Lead sponsor
Andrew Ko
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2020 · Synced Oct 30, 2026, 7:16 AM EDT
Completed Phase 3 Interventional Results available

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults

NCT01231516
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK1349572, Raltegravir, GSK1349572 Placebo, Raltegravir Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 30, 2026, 7:16 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

NCT02641561
View directory record Official record
Conditions
Post-ERCP Acute Pancreatitis
Interventions
Indomethacin, Lactated Ringer's Solution, Normal Saline, Placebo
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 30, 2026, 7:16 AM EDT
Completed Early Phase 1 Interventional

Losartan in Prevention of Radiation-Induced Heart Failure

NCT05607017
View directory record Official record
Conditions
Breast Cancer, Myocardial Fibrosis, Radiation-Induced Fibrosis
Interventions
Losartan, Radiation Therapy
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 30, 2026, 7:16 AM EDT
Completed Phase 4 Interventional Results available

Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension

NCT02653560
View directory record Official record
Conditions
Hypertension
Interventions
Potassium chloride powder, Potassium magnesium Citrate (KMgCit), Potassium citrate powder, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 30, 2026, 7:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Oral Irritation Study of Two Experimental Mouthrinses

NCT01156376
View directory record Official record
Conditions
Oral Manifestations
Interventions
Potassium Oxalate without Fluoride, Potassium Oxalate with Fluoride, Active Comparator PO-116-A
Device
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 30, 2026, 7:16 AM EDT
Withdrawn Phase 3 Interventional

Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women

NCT00984152
View directory record Official record
Conditions
HIV-1 Infections
Interventions
TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily, TDF/FTC + Efavirenz (Atripla) Once-Daily
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 30, 2026, 7:16 AM EDT
Completed Phase 3 Interventional Results available

Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)

NCT00577135
View directory record Official record
Conditions
Heart Failure
Interventions
Furosemide-Q12 hour bolus, Furosemide-Continuous Infusion, Furosemide-Low Intensification, Furosemide-High Intensification
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
Atlanta, Georgia • Boston, Massachusetts • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Oct 30, 2026, 7:16 AM EDT
Recruiting Phase 4 Interventional

Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis

NCT06076304
View directory record Official record
Conditions
Sinus Infection, Acute Sinusitis
Interventions
amoxicillin/clavulanate potassium, Placebo, Budesonide nasal spray
Drug
Lead sponsor
Daniel Merenstein
Other
Eligibility
18 Years to 75 Years
Enrollment
3,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Hyattsville, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 30, 2026, 7:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy Volunteers

NCT01531647
View directory record Official record
Conditions
Healthy Volunteer
Interventions
danoprevir, raltegravir, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 30, 2026, 7:16 AM EDT
Recruiting Phase 4 Interventional

Low Sodium Oxybate in Patients With Idiopathic Hypersomnia

NCT05837091
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
Low Sodium Oxybate, 24-hour polysomnography, Nextsense EEG earbuds, Axivity device
Drug · Diagnostic Test · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Redwood City, California • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 30, 2026, 7:16 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients

NCT01074918
View directory record Official record
Conditions
Pre-hypertension, Hypertension
Interventions
Potassium, Magnesium, Citrate, Potassium Chloride
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 95 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Oct 30, 2026, 7:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nitric Oxide Flux and Ureagenesis in Argininosuccinate Synthetase Deficiency (ASSD)(Citrullinemia I)

NCT01610089
View directory record Official record
Conditions
Citrullinemia
Interventions
stable isotope infusion
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2015 · Synced Oct 30, 2026, 7:16 AM EDT
Completed Phase 4 Interventional Results available

Acute Otitis Media (AOM) Therapy Trial in Young Children

NCT00377260
View directory record Official record
Conditions
Acute Otitis Media
Interventions
amoxicillin-clavulanate, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Months to 23 Months
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 30, 2026, 7:16 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Phase 2B/3 Double-blinded Placebo-controlled

NCT03107377
View directory record Official record
Conditions
Chlamydia Trachomatis Infection
Interventions
EVO100, Placebo
Drug
Lead sponsor
Evofem Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
860 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
50
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 30, 2026, 7:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Methadone Maintenance Therapy on Food Reward Processing in Opioid Dependence

NCT03575273
View directory record Official record
Conditions
Opioid Dependence, Obesity
Interventions
Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio (PR) Task, Clinical Electrophysiology, Standardized Meal and Hunger and Satiety Ratings
Behavioral · Procedure · Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 30, 2026, 7:16 AM EDT
Completed Phase 2 Interventional

Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy

NCT00041795
View directory record Official record
Conditions
Peripheral Nervous System Diseases, Chemotherapy-Induced Peripheral Neuropathy
Interventions
leteprinim potassium (Neotrofin)
Drug
Lead sponsor
NeoTherapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
6
States / cities
Berkeley, California • Burbank, California • Mission Hills, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 7:16 AM EDT